Insulin Aspart
Injectable Suspension · trading as Insulin Aspart Protamine And Insulin Aspart Mix 70/30
To Be Discontinued
FDA shortage record
- Substance
- Insulin Aspart
- Brand name
- Insulin Aspart Protamine And Insulin Aspart Mix 70/30
- Manufacturer
- Novo Nordisk Pharma, Inc.
- Dosage form
- Injectable Suspension
- Presentation
- Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)
- Route(s)
- SUBCUTANEOUS
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
73070-200-11- Initially posted
- 07/21/2025
- Discontinued
- 07/21/2025
- Current FDA status
- To Be Discontinued
Reason and context
Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 609-987-5800.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
fc94baa4-3606-48bc-a781-9617ab6960ef). - FDA UNII identifier:
D933668QVX. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.